

Invitation to conference call and webcast today 3 November, at 14.30 CET

Medivir will be conducting an analyst and investor conference call/webcast today 3 November, at 14.30 CET. Niklas Prager CEO, Ola Burmark CFO and Richard Bethell CSO will be presenting and will be available for questions relating to the recent agreement to acquire two clinical stage oncology programs from Tetralogic Pharmaceuticals Corporation.

To join the conference call, please dial:

Sweden +46 (0)8 566 426 96

Europe +44 20 300 898 17

USA +1 855 831 5946

The webcast can be accessed on the website: www.medivir.com.

For further information, please contact:

Niklas Prager, CEO and President Medivir AB, +46 8 407 6430

Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

Richard Bethell, CSO Medivir AB, mobile +46 (0)72 704 3211

About Medivir

Medivir is a research based pharmaceutical company with a research focus on oncology and infectious diseases. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.